IMD business school for management and leadership courses

Abbott Laboratories accelerated its AI agenda over the past 18 months. At the January 2024 J.P. Morgan Healthcare Conference, CEO Robert Ford publicly framed AI as a pillar for growth, and soon after, the firm elevated AI-savvy CIO Sabina Ewing to the executive suite. Abbott created the Lingo™ consumer-wearable business, its first division built around AI-driven metabolic coaching, and secured FDA clearance and a CES Innovation Award within a year. On the clinical-infrastructure side, LibreView® data now flows into Epic® EHRs, giving more than half a million US clinicians real-time glucose analytics, while an AI-guided TAVI system signals ambitions in intelligent procedures.  

Internally, machine-learning models already bolster quality-risk prediction, and generative AI (GenAI) courses are offered to employees. Governance matured in parallel: the executive Data Use & Ethics Board set enterprise AI principles, and Abbott published a five-point Responsible AI framework pledging safety, fairness, and transparency. Collectively, the company moved from vision statements to deployed products, infrastructure integrations, workforce enablement, and formal ethics, positioning Abbott to scale trusted AI across diagnostics, devices, and consumer health.